...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: BETonMACE Enrollment

I don't know why I didn't think of this before but it seems to me that when we are talking about the timing of the Futility Analysis we are assuming that the test arm will have a relatively uniform response. To me it would seem possible that the test arm could have two distinctly different subsets, as in ASSURE. Since one group in the test arm is on Apabetalone + atorvastatin and the other is on Apabetalone + rosuvastatin it would seem that there is more room for various outcomes and thus influence the timing of reaching 125 events. Bear do you think this is valid logic?   

Share
New Message
Please login to post a reply